Tenet Healthcare Corporation (THC)
| Market Cap | 16.40B +38.8% |
| Revenue (ttm) | 21.46B +4.5% |
| Net Income | 1.70B +17.0% |
| EPS | 19.14 +26.8% |
| Shares Out | 86.14M |
| PE Ratio | 9.95 |
| Forward PE | 10.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,240,928 |
| Open | 196.11 |
| Previous Close | 194.13 |
| Day's Range | 188.88 - 198.43 |
| 52-Week Range | 146.60 - 247.21 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 238.75 (+25.41%) |
| Earnings Date | Apr 30, 2026 |
About THC
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient... [Read more]
Financial Performance
In 2025, Tenet Healthcare's revenue was $21.31 billion, an increase of 3.07% compared to the previous year's $20.68 billion. Earnings were $1.41 billion, a decrease of -56.03%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for THC stock is "Strong Buy." The 12-month stock price target is $238.75, which is an increase of 25.41% from the latest price.
News
Tenet to Participate in the BofA Securities Health Care Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the BofA Securities Health Care Conference on Wednesday, May 13, 2026.
Tenet Healthcare price target lowered to $210 from $245 at Baird
Baird lowered the firm’s price target on Tenet Healthcare (THC) to $210 from $245 and keeps a Neutral rating on the shares. The firm updated its model ahead of Q3
Tenet Healthcare price target lowered to $238 from $257 at Barclays
Barclays analyst Andrew Mok lowered the firm’s price target on Tenet Healthcare (THC) to $238 from $257 and keeps an Overweight rating on the shares post the Q1 report. The
Tenet Healthcare price target lowered to $260 from $275 at Stephens
Stephens analyst Scott Fidel lowered the firm’s price target on Tenet Healthcare (THC) to $260 from $275 and keeps an Overweight rating on the shares. The firm adjusted estimates following
Tenet Healthcare price target lowered to $254 from $260 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tenet Healthcare (THC) to $254 from $260 and keeps an Overweight rating on the shares. Tenet’s consistent execution was on display on
Tenet Healthcare selloff overdone, compelling longer term, says Cantor
Tenet Healthcare’s (THC) long-term growth story remains intact after Q1, with a clean EBITDA beat and no meaningful change to the underlying narrative despite an in-line print, as near-term noise
Tenet Healthcare price target lowered to $225 from $250 at KeyBanc
KeyBanc lowered the firm’s price target on Tenet Healthcare (THC) to $225 from $250 and keeps an Overweight rating on the shares. The firm notes Q1 results were solid, highlighted
Tenet Healthcare price target lowered to $252 from $283 at Guggenheim
Guggenheim lowered the firm’s price target on Tenet Healthcare (THC) to $252 from $283 and keeps a Buy rating on the shares. Q1 EBITDA upside “layers another proof-point that THC
Tenet Healthcare Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues of $5.4B and adjusted EBITDA of $1.16B, both above expectations, driven by disciplined expense management and strong USPI and hospital segment performance. Guidance for 2026 is reaffirmed, with robust cash flow and continued capital deployment for growth and share repurchases.
Tenet Healthcare reports Q1 adjusted EPS $4.82, consensus $4.17
Reports Q1 revenue $5.37B, consensus $5.4B. “We delivered strong results in both the Ambulatory and Hospital segments in the first quarter of 2026, characterized by disciplined operations and strong f...
Tenet Healthcare backs FY26 adjusted EBITDA view $4.485B-$4.785B
06:50 EDT Tenet Healthcare (THC) backs FY26 adjusted EBITDA view $4.485B-$4.785B
Tenet Healthcare sees FY26 adjusted EPS $16.38-$18.68, consensus $17.19
Sees FY26 revenue $21.5B-$22.3B, consensus $22.02B.
Tenet Reports Strong First Quarter 2026 Results
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended March 31, 2026. "We delivered strong results in both the Ambulatory and Hosp...
Tenet to Report its First Quarter 2026 Results on April 30th
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its first quarter 2026 results before the market opens on Thursday, April 30, 2026, to be followed by a conference call a...
Tenet Healthcare price target raised to $283 from $271 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $283 from $271 and keeps a Buy rating on the shares. Despite Tenet’s roughly 90% return over the past
Tenet Healthcare price target raised to $265 from $235 at Mizuho
Mizuho raised the firm’s price target on Tenet Healthcare (THC) to $265 from $235 and keeps an Outperform rating on the shares. The firm updated the company’s model post the
Unusually active option classes on open March 11th
Unusual total active option classes on open include: Tenet (THC), Shoals Technologies Group (SHLS), Serve Robotics Inc (SERV), AXT (AXTI), Kosmos (KOS), PureFunds Junior Silver Small Cap (SILJ), Enovi...
Tenet Healthcare Transcript: Barclays 28th Annual Global Healthcare Conference
Strong demand for high-acuity care and disciplined capital deployment support robust growth projections. AI and automation drive efficiency, while commercial rates remain favorable and ambulatory expansion continues. Capital priorities include service line investment, share buybacks, and debt reduction.
Tenet to Participate in the Barclays 28th Annual Global Healthcare Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, beginning at 9:30 a.m. Ea...
Tenet Healthcare price target raised to $270 from $240 at Truist
Truist raised the firm’s price target on Tenet Healthcare (THC) to $270 from $240 and keeps a Buy rating on the shares. The firm is adjusting its model after the
Tenet Healthcare price target raised to $265 from $229 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Tenet Healthcare (THC) to $265 from $229 and keeps an Overweight rating on the shares. The magnitude of the
Tenet Healthcare price target raised to $271 from $257 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $271 from $257 and keeps a Buy rating on the shares after the company reported Q4 EBITDA in line
Tenet Healthcare Earnings Call Transcript: Q4 2025
2025 saw strong revenue and margin growth, with Adjusted EBITDA up 14% and robust free cash flow. 2026 guidance anticipates continued growth, though headwinds from expiring tax credits are expected. Capital deployment remains focused on M&A, share repurchases, and technology-driven efficiencies.
Tenet Reports Strong Fourth Quarter and FY 2025 Results; Provides 2026 Financial Outlook
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended December 31, 2025. "2025 extended Tenet's track record of strong revenue gro...
Tenet Healthcare Transcript: Status update
An accretive $2.65 billion asset sale of Conifer's contract with CommonSpirit strengthens cash flow, returns full strategic control, and enables accelerated investment in automation, AI, and offshoring. Capital allocation priorities remain focused on share repurchases and USPI growth.